NAV2
Overview
NAV2 (Neuron Navigator 2) encodes a microtubule-binding protein involved in neuronal guidance and cytoskeletal organization. In colorectal cancer, NAV2 was identified as a fusion partner with the WNT transcription factor TCF7L1, representing a recurrent structural rearrangement that disrupts beta-catenin-dependent signaling.
Alterations observed in the corpus
- Recurrent NAV2-TCF7L1 fusion detected in 3 colorectal cancer cases (276-tumor TCGA CRC cohort); fusion causes TCF7L1 to lose its beta-catenin binding domain PMID:22810696
Cancer types (linked)
- Colorectal adenocarcinoma (COAD/READ): recurrent NAV2-TCF7L1 fusion in 3/276 tumors; implicates WNT pathway disruption via structural rearrangement PMID:22810696
Co-occurrence and mutual exclusivity
- NAV2-TCF7L1 fusion co-occurs in colorectal tumors lacking APC or CTNNB1 mutations; suggests alternative WNT pathway activation mechanism PMID:22810696
Therapeutic relevance
- No direct therapeutic targeting established; WNT pathway disruption may be relevant for emerging WNT inhibitor strategies.
Open questions
- Functional consequence of NAV2-TCF7L1 fusion on TCF7L1 transcriptional activity is inferred but not experimentally validated in the TCGA CRC study.
Sources
This page was processed by entity-page-writer on 2026-05-06.